Johnson & Johnson appoints Yana Ignatova

Ignatova, who joins from Procter & Gamble, will oversee all franchises.

Johnson & Johnson has announced the appointment of Yana Ignatova as Head of Marketing, Northern Europe.

Ignatova, who joins from Procter & Gamble, will oversee all franchises – Baby, Beauty, Consumer Health/Nutritionals and OTC, driving best in class marketing across the business. This is the first time that all franchises have been brought together under one marketing lead.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Skin Care

J&J recalls Clean & Clear Facial Cleansers in the US due to micro contamination

An FDA enforcement report notice states the company is voluntarily recalling at wholesale level 7,800 bottles of Clean & Clear’s Morning Burst Facial Cleanser
Skin Care

Neutrogena signs Olympic gold medalist Sydney McLaughlin-Levrone as ambassador

The US track star will represent the skin care brand alongside existing ambassadors Jenna Ortega and Chloe and Halle Bailey
Skin Care

J&J to hold 9.5% stake in consumer health spinoff Kenvue following share exchange

The multinational launched the exchange offer in July in a bid to take its hands off the Kenvue reins
Regulatory

Johnson & Johnson to appeal $19 million owed to California cancer patient

The talc cancer trial involving 24-year-old Emory Hernandez Valadez was the first faced by J&J since its bankruptcy filing
You need to be a subscriber to read this article.
Click here to find out more.
Colour Cosmetics

Metaverse Beauty Week day 4 review - madcap mushrooms and nonsensical buildings shadow over potential

The Cosmetics Business editorial team will be reviewing each day of Metaverse Beauty Week 2023, 12-17 June
Regulatory

Johnson & Johnson faces first new talc cancer trial since bankruptcy filing

Judge overseeing LTL Management’s Chapter 11 has allowed the trial to go ahead, as 24-year-old cancer patient Anthony Hernandez Valadez does not have long to live

Johnson & Johnson’s Kenvue valued at around $41 billion in IPO

The health care giant’s new consumer health arm priced above the middle of the expected range ahead of trading on the New York Stock Exchange
Subscribe now